The reference price system and socioeconomic differences in the use of low cost drugs : Supplement

VIII, 69 p. ill. APPENDICES WITH CHAPTER 2.2 -- 1 SOURCES FOR THE INTERNATIONAL REFERENCE PRICING COMPARISON.2 -- 2 COUNTRY OVERVIEW - CRITERIA DEFINING GROUPS OF DRUGS.6 -- Category 1: Countries with a Level 1 RPS.6 -- Category 2: Countries with a Level 2 RPS.6 -- Category 3: Countries with a multilevel RPS.7 -- 3 COUNTRY OVERVIEW - CRITERIA TO DETERMINE THE REFERENCE PRICE.8 -- Category 1: Countries with a Level 1 RPS.8 -- Category 2: Countries with a Level 2 RPS.8 -- Category 3: Countries with a multilevel RPS.9 -- 4 COUNTRY OVERVIEW - MEASURES FOR PHYSICIANS, PHARMACISTS AND PATIENTS 10 -- Category 1: Countries with a Level 1 RPS.10 -- Category 2: Countries with a Level 2 RPS.12 -- Category 3: Countries with a multilevel RPS.13 -- APPENDICES WITH CHAPTER 3.15 -- 5 ASSOCIATION OF THE RPS WITH OUTCOME MEASURES: REVIEW OF INDIVIDUAL -- STUDIES.15 -- Association of the RPS with drug use.15 -- Association of the RPS with drug prices.17 -- Association of the RPS with drug expenditures.18 -- Association of the RPS with health services use and health.20 -- APPENDICES WITH CHAPTER 4.27 -- 6 RESULTS FOR 12 MOLECULES, CHOICE OF A LOW COST OR HIGH COST ORIGINAL 28 -- 7 PATIENTS USING THE “LEAST COSTLY” MOLECULE(S) WITHIN A CLASS OF DRUGS.40 -- 7.1 Percentage of patients.40 -- 7.2 Regression results.43 -- 7.3 Results from contrast statement: unemployed versus employed.47 -- REFERENCES.48